利伐沙班与低相对分子质量肝素预防人工髋膝关节置换术后静脉血栓栓塞症的前瞻性随机对照研究被引量：22

Rivaroxaban versus low molecular weight heparin in prevention of venous thromboembolism in patients undergoing hip or knee arthroplasty

原文传递

导出

摘要目的通过比较利伐沙班与低相对分子质量肝素（LMWH）对静脉血栓栓塞症（VTE）的预防作用,评价两者预防人工全髋关节置换术（THA）和全膝关节置换术（TKA）后VTE的有效性与安全性.方法 2009年8月至2010年7月共收治84例行THA和TKA的患者,随机分为利伐沙班组和LMWH组,利伐沙班组48例,男13例,女35例平均年龄63.9岁 THA 25例,其中1例行双侧置换术 TKA23例,其中10例行双侧置换术.LMWH组36例,男10例,女26例平均年龄57.2岁 THA 16例,其中5例行双侧置换术 TKA 20例,其中6例行双侧置换术.THA患者术后第1～35天、TKA患者术后第1～14天,利伐沙班组给予利伐沙班10 mg,1次/d,口服 LMWH组给予LMWH 0.4 mL,1次/d,皮下注射. 结果两组患者围手术期失血量差异均无统计学意义（P＞0.05）.所有患者术后获3个月随访.利伐沙班组深静脉血栓形成（DVT）发生率为20.8%（10/48）,LMWH组DVT发生率为25.0%（9/36）,两组比较差异无统计学意义（χ2=0.204,P=0.651）.两组患者均未发生症状性肺栓塞. 结论利伐沙班能有效预防THA、TKA后下肢DVT的发生,同时具有良好的安全性,其疗效与LMWH相当,且不会增加出血等并发症. Objective To evaluate the efficacy and safety of Rivaroxaban versus low molecular weight heparin （LMWH） in prevention of venous thromboembolism （VTE） after total hip or knee arthroplasty.Methods From August, 2009 to July, 2010, 84 patients were recruited in this study. Under randomization, 48 were assigned into the observation group of Rivaroxaban and 36 into the control group of LMWH.The observation group had 13 males and 35 females, including 25 cases of total hip arthroplasty （THA） and 23 cases of total knee arthroplasty （TKA）. The control group had 10 males and 26 females, including 16 cases of THA and 20 cases of TKA. Oral Rivaroxaban （10 mg once per day） was administered for THA patients from day 1 to 35 postoperatively and for TKA patients from days 1 to 14 postoperatively. Hypodermic injection of LMWH （0. 4mL once per day） was administered for THA patients from days 1 to 35 postoperatively and for TKA patients from days 1 to 14 postoperatively. Results All the patients were followed up for 3 months.The VTE rate was 20. 8% （10/48） in the observation group, and 25.0% （9/36） in the control group. The difference between the 2 groups was insignificant （χ2 =0. 204, P =0. 651）. There was no significant difference either in intraoperative postoperative bleeding between the 2 groups （P 〉 0. 05）. No symptoms of pulmonary embolism were observed in either group. Conclusions The clinical efficacy and safety of Rivaroxaban is comparable to LMWH in reducing the incidence of VTE after THA or TKA. Rivaroxaban is associated with low risks of hematomas, delayed wound healing, and postoperative infection.

作者权冬朱锦宇王华溢刘雯朱庆生

机构地区第四军医大学附属西京医院骨科第四军医大学口腔医院医教部

出处《中华创伤骨科杂志》 CAS CSCD 2010年第12期1130-1134,共5页 Chinese Journal of Orthopaedic Trauma

关键词静脉血栓形成关节成形术置换肝素低分子量利伐沙班 Venous thrombosis Arthroplasty, replacement Heparin, low molecular weight Rivaroxaban

分类号 R686 [医药卫生—骨科学]

引文网络
相关文献

参考文献16

1Geerts WH,Heit JA,Clagett GP,et al.Prevention of venous thromboembolism.Chest,2001,119(1 Suppl):132S-175S.
2陆慰萱,王辰主编.肺循环病学.北京:人民卫生出版社,2007.
3纪泉,赵立连,张耀南,黄公怡.人工关节置换术与深静脉血栓形成[J].中华创伤骨科杂志,2006,8(6):573-576. 被引量：20
4Lieberman JR,Geerts WH.Prevention of venous thromboembolism after total hip and knee arthroplasty.J Bone Joint Surg(Am),1994,76:1239-1250.
5Gross JB.Estimating allowable blood loss:corrected for dilution.Anesthesiology,1983,58:277-280.
6Nadler SB,Hidalgo JU,Bloch T.Prediction of blood volume in normal human adults.Surgery,1962,51:224-232.
7Kassim RA,Saleh KJ,Badra M,et al.Thromboembolic complicatios after total hip arthroplasty.J South Orthop Assoc,2003,12:103-105.
8White RH,Henderson MC.Risk factors for venous thromboembolism after total hip and knee replacement surgery.Curr Opin Pulm Med,2002,8:365-371.
9Parisi R,Visonà A,Camporese G,et al.Isolated distal deep vein thrombosis:efficacy and safety of a protocol of treatment.Treatment of Isolated Calf Thrombosis (TICT) Study.Int Angiol,2009,28:68-72.
10中国骨科大手术静脉血栓栓塞症预防指南[J].中华骨科杂志,2009,29(6):602-604. 被引量：534

二级参考文献47

1邱贵兴,杨庆铭,余楠生,翁习生,王凯,李晓林.低分子肝素预防髋、膝关节手术后下肢深静脉血栓形成的多中心研究[J].中华骨科杂志,2006,26(12):819-822. 被引量：431
2Ollendorf DA,Vera-Llonch M,Oster G.Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.Am J Health Syst Pharm,2002,59(18):1750-1754.
3Geerts WH,Pineo OF,Heir JA,et al.Prevention of venous thromboembolism:the Seventh ACCP Conference on Antithromboric and Thrombolytic Therapy.Chest,2004,126 (3 Suppl):S338-400.
4Mosby's Dictionary of Medicine,Nursing & Health Professions.7th ed.St.Louis,MO:Mosby,2006:115-116,335,520,1454,1849,1949.
5Piovella F,Wang CJ,Lu H,et al.Deep-vein thrombosis rates after major Orthopedic surgery in Asia:an epidemiological study based on postoperative screening with centrally adjudicated bilateral venography.J Thromb Haemost,2005,3(12):2664-2670.
6Heir JA,O'Fallon WM,Petterson TM,et al.Relative impact of risk factors for deep vein thrombosis and pulmonary embolism:a population-based study.Arch Intern Med,2002,162 (11):1245-1248.
7Anderson FA Jr,Spencer FA.Risk factors for venous thrombcembolism.Circulation,2003,107(23 Suppl 1):9-16.
8Caprini JA.Thrombosis risk assessment as a guide to quality patient care.Dis Mon,2005,51(2/3):70-78.
9Geerts WH,Heit JA,Clagett GP,et al.Prevention of venous thromboembolism.Chest,2001,119(1 Suppl):S132-175.
10Snow V,Qaseem A,Barry P,et al.Management of venous thromboembolism:a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.Ann Intern Med,2007,146(3):204-210.